Research library
MOTS-c Research Overview: Mitochondrial-Derived Peptide Signalling and Metabolic Study Findings
- Compiled by:
- Peptide Pilots Scientific Content Team
- Reviewed by:
- Peptide Pilots Quality & Compliance review
- Last revised:
What has been published about MOTS-c's mechanism and metabolic effects, and how far does the evidence extend into humans?
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene rather than the nuclear genome, identified in 2015 as one of several 'mitochondrial-derived peptides.' Cell and rodent studies report that MOTS-c translocates to the nucleus under metabolic stress, regulates nuclear gene expression via AMPK-dependent pathways, and influences glucose uptake and insulin sensitivity in skeletal muscle. Rodent work associates administration with improved glucose handling and reduced diet- and age-related metabolic decline. Human data are limited to observational genetic-variant association studies and a small number of early-phase exercise-physiology reports; there is no published randomised controlled trial establishing clinical efficacy for a metabolic indication.
This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.
What is MOTS-c?
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a short peptide translated from an alternative open reading frame within the mitochondrial genome's 12S rRNA region, distinguishing it from nuclear-DNA-encoded peptide hormones.
In laboratory work it is studied as a circulating and intracellular signalling peptide, with particular attention to skeletal muscle, adipose tissue and the AMPK–nuclear gene-expression axis under metabolic stress such as exercise, fasting or high-fat feeding.
MOTS-c names and identifiers
Also referred to as: mitochondrial open reading frame of the 12S rRNA type-c; MOTS-c peptide
| Sequence (one-letter) | MRWQEMGYIFYPRKLR |
|---|---|
| Residue count | 16 amino acids |
| Molecular formula | C99H153N29O16S |
| Average molecular weight | ≈2174.6 g/mol |
| Genomic origin | Alternative open reading frame within mitochondrial 12S rRNA (MT-RNR1) |
| CAS number | 1627580-64-6 |
MOTS-c research background
MOTS-c was first reported in 2015 by a research group studying small peptides encoded within mitochondrial DNA, following earlier identification of the related mitochondrial-derived peptide humanin.
Initial characterisation described nuclear translocation of MOTS-c under metabolic stress and regulation of genes involved in antioxidant response and glucose metabolism, positioning it as a candidate mediator of mitochondrial-to-nuclear retrograde signalling.
Subsequent rodent studies examined effects on diet-induced and age-related insulin resistance, and a genetic-epidemiology literature has examined a common MOTS-c coding variant (K14Q) for associations with metabolic and longevity phenotypes in specific populations. The central open question is whether pharmacological administration in humans reproduces the metabolic effects reported in mice.
Proposed MOTS-c mechanisms and pathways
Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.
MOTS-c in-vitro and cell-based evidence
- Cell studies report that MOTS-c translocates to the nucleus in response to metabolic stress (e.g., glucose restriction or oxidative stress) and binds nuclear transcription-factor complexes, including NRF2-associated elements, to regulate antioxidant-response gene expression.
- Skeletal-muscle cell studies report activation of AMPK signalling and increased glucose uptake following MOTS-c exposure, independent of insulin.
- Reported effects on folate-methionine one-carbon metabolism have been proposed as an additional link between MOTS-c and cellular stress adaptation, though this mechanism is less thoroughly replicated than the AMPK pathway.
MOTS-c animal-model evidence
- Mice fed a high-fat diet and treated with MOTS-c showed reduced weight gain and improved glucose tolerance and insulin sensitivity compared with untreated controls in the originating laboratory's reports.
- Aged mice treated with MOTS-c showed improved insulin sensitivity and physical performance measures relative to age-matched controls in the same research programme.
- Exercise-associated increases in circulating MOTS-c have been reported in rodent models, supporting its proposed role as an exercise-responsive myokine-like signal, though the magnitude and consistency of this response vary across studies.
Published MOTS-c human-study evidence
- Cross-sectional studies have measured circulating MOTS-c levels in relation to age, exercise status and metabolic disease, reporting associations that are correlational rather than interventional.
- Genetic-association studies of the MOTS-c m.1382A>C (K14Q) variant have reported population-specific associations with longevity and metabolic traits in some East Asian cohorts, with inconsistent replication elsewhere.
- No peer-reviewed randomised controlled trial of exogenous MOTS-c administration reporting clinical metabolic endpoints in humans has been published.
Published MOTS-c studies
| Study | Model / type | Research question | Main observation | Citation |
|---|---|---|---|---|
| Lee et al., original characterisation | Human cell lines and mice | Does a mitochondrial-DNA-encoded peptide regulate nuclear metabolic gene expression? | Identified MOTS-c, described nuclear translocation under stress and AMPK-dependent regulation of glucose metabolism. | Cell Metabolism, 2015 |
| Reynolds et al., insulin-resistance model | High-fat-fed and aged mice | Does MOTS-c administration alter diet- and age-associated insulin resistance? | Reported improved glucose tolerance and insulin sensitivity with MOTS-c treatment versus controls. | Nature Communications, 2021 |
| Kim et al., exercise physiology | Human observational cohort | Does circulating MOTS-c change with acute or chronic exercise? | Reported associations between exercise status and circulating MOTS-c concentrations; interventional causality was not established. | Cell Metabolism, 2018 |
| Fuku et al., genetic-variant association | Human cohort, genotype-phenotype association | Is the MOTS-c K14Q variant associated with longevity or metabolic phenotypes? | Reported population-specific associations with longevity in a Japanese cohort; replication across ethnic groups is inconsistent. | Aging Cell, 2015 |
Limitations of the MOTS-c evidence
- Most mechanistic and efficacy data come from a small number of laboratories and from mouse models; independent replication of the metabolic-improvement findings is limited.
- Human data are almost entirely observational (circulating-level or genetic-association studies), which cannot establish that administering the peptide causes any metabolic change.
- No published randomised, placebo-controlled human trial has assessed exogenous MOTS-c for a metabolic or performance endpoint.
- Pharmacokinetic data in humans (absorption, half-life, distribution) are sparse, complicating interpretation of any observed circulating-level associations.
- The K14Q variant literature shows population-specific effects that do not necessarily generalise, and association is not evidence of the mechanism proposed from mouse and cell studies.
MOTS-c laboratory characteristics
Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.
| Appearance | White to off-white lyophilised powder |
|---|---|
| Solubility | Soluble in water and dilute acetic acid; sonication may assist dissolution |
| Lyophilised storage | Commonly stored at −20 °C, desiccated and protected from light |
| Reconstituted handling | Refrigerated storage with short working periods is standard laboratory practice |
| Analytical testing | RP-HPLC purity and MS identity per lot; sequence confirmation by MS/MS where required |
| Stability considerations | Peptide contains a single methionine and no cysteines; oxidation of methionine is the main documented degradation route |
Frequently asked MOTS-c research questions
What makes MOTS-c different from most research peptides?
It is encoded within mitochondrial DNA (the 12S rRNA region) rather than the nuclear genome, placing it in the small class of 'mitochondrial-derived peptides' alongside humanin.
What pathway is most consistently reported for MOTS-c?
AMPK-dependent regulation of nuclear gene expression and skeletal-muscle glucose uptake is the most consistently reported mechanism across cell and rodent studies.
Has MOTS-c been tested in human clinical trials?
No peer-reviewed randomised controlled trial of exogenous MOTS-c administration in humans has been published. Human data are limited to observational and genetic-association studies.
Is the MOTS-c genetic variant relevant to everyone?
The K14Q coding variant associated with longevity in some reports is population-specific, most notably in East Asian cohorts, and does not necessarily generalise to other populations.
MOTS-c primary references
- Lee C, Zeng J, Drew BG, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. https://doi.org/10.1016/j.cmet.2015.02.009
- Reynolds JC, Lai RW, Woodhead JST, et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. https://doi.org/10.1038/s41467-020-20790-0
- Kim KH, Son JM, Benayoun BA, Lee C (2018). The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. https://doi.org/10.1016/j.cmet.2018.06.008
- Fuku N, Pareja-Galeano H, Zempo H, et al. (2015). The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?. Aging Cell. https://doi.org/10.1111/acel.12389
Authorship and revision
Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published ; last revised . Pages are revised when the cited literature changes materially.
Catalogue reference
Peptide Pilots supplies MOTS-C as a laboratory reagent with per-lot RP-HPLC and mass-spectrometry documentation. Quantities, testing, packaging and fulfilment details are on the catalogue page.
Related catalogue products
Laboratory reagents supplied by Peptide Pilots from the Weight-Management Research tier. Research use only; not for human or veterinary use.
